Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

This study has been completed.

Sponsor:

Collaborator:

University of Athens

Information provided by:

Aristotle University Of Thessaloniki

ClinicalTrials.gov Identifier:

NCT00306176

First received: March 22, 2006

Last updated: April 3, 2007

Last verified: April 2007

History of Changes

Purpose

The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors

Condition	Intervention	Phase
Type II Diabetes Mellitus	Drug: Rosiglitazone	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Diabetes Type 2 Exercise and Physical Fitness

Drug Information available for: Rosiglitazone Rosiglitazone Maleate

U.S. FDA Resources

Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:

Cardiovascular risk factors alterations

Estimated Enrollment:	100
Study Start Date:	January 2005
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	40 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Type II diabetes mellitus
Poor glycemic control

Exclusion Criteria:

Heart failure
Renal disease
Liver disease
Cardiovascular event

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00306176

Locations

Greece
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece, 54454

Sponsors and Collaborators

Aristotle University Of Thessaloniki

University of Athens

Investigators

Study Chair:

Christos Liapis, PhD,MD

University of Athens,Greece

More Information

No publications provided by Aristotle University Of Thessaloniki

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kadoglou NP, Vrabas IS, Kapelouzou A, Angelopoulou N. The association of physical activity with novel adipokines in patients with type 2 diabetes. Eur J Intern Med. 2012 Mar;23(2):137-42. Epub 2011 Nov 29.

Kadoglou NP, Vrabas IS, Sailer N, Kapelouzou A, Fotiadis G, Noussios G, Karayannacos PE, Angelopoulou N. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab. 2010 Apr;36(2):144-51. Epub 2010 Feb 9.

Kadoglou NP, Iliadis F, Angelopoulou N, Sailer N, Fotiadis G, Voliotis K, Vitta I, Liapis CD, Alevizos M. Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications. 2009 May-Jun;23(3):160-6. Epub 2008 Apr 16.

Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2242-4. Epub 2007 Jun 22. No abstract available.

ClinicalTrials.gov Identifier:	NCT00306176 History of Changes
Other Study ID Numbers:	1975
Study First Received:	March 22, 2006
Last Updated:	April 3, 2007
Health Authority:	Greece: National Organization of Medicines

Keywords provided by Aristotle University Of Thessaloniki:

rosiglitazone,exercise,cardiovascular risk factors

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013

To Top